earnings
confidence high
sentiment neutral
materiality 0.60
AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes
AbCellera Biologics Inc.
2025-Q1 EPS reported
-$0.15
revenue$4,235,000
- Total revenue $4.2M, down 58% from $10.0M in Q1 2024.
- Net loss $45.6M ($0.15/share) vs net loss $40.6M ($0.14) year ago.
- Announces ABCL635, a first-in-class NK3R antibody for vasomotor symptoms from menopause; Phase 1 expected H2 2025.
- Available liquidity ~$810M ($633M cash + $178M government funding).
- Cumulative partner program starts 97, clinic molecules 16; R&D spend up to $42.5M.